Overview
- 4 inspections across 4 sites are on record.
- 9 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2025-08-01.
At a glance
Inspections
4
Sites
4
Observations
9
Career since
Sep 2014
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Daiichi Sankyo, Inc. | 1 Aug 2025 | Human Drugs | View 483 → |
| Bausch Health US., LLC. | 16 May 2019 | Human Drugs | |
| STI Pharma LLC | 21 Jul 2016 | Human Drugs | View 483 → |
| Amarin Pharma Inc. | 9 Sep 2014 | Human Drugs | View 483 → |
Sites inspected
Daiichi Sankyo, Inc.Basking Ridge, United States1 insp.
Bausch Health US., LLC.Bridgewater, United States1 insp.
STI Pharma LLCNewtown, United States1 insp.
Amarin Pharma Inc.Bedminster, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Mayar M Mussa1 shared
Michael Serrano1 shared
Matthew R Noonan1 shared
David A Oluwo1 shared
Liatte Krueger1 shared
Full investigator report
Get the verbatim findings behind Namita Kothary's 9 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site